Tagrix

Osimertinib (Tagrix) is the 1st and only drug of its kind approved by USFDA for the treatment of epidermal growth factor receptor (EGFR) positive Non- Small Cell Lung Cancer (NSCLC) patient with T790M mutation. TAGRIX is indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).

Features